Laura E. Niklason

Insider Reports History

Reporting-owner location: Greenwich, CT
Latest reporting-owner signature: /s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Laura E. Niklason

Form 4 holding President, CEO and Director, Director

Humacyte, Inc.

Security class: Common Stock
Shares / value: 1,148,240
Estimated value: $2,790,223
Report date: 18 Aug 2025
Price: $2.43
Ownership: By The Niklason Living Trust

Form 4 holding President, CEO and Director, Director

Humacyte, Inc.

Security class: Common Stock
Shares / value: 243,851
Estimated value: $592,557
Report date: 18 Aug 2025
Price: $2.43
Ownership: Direct

Form 4 holding President, CEO and Director, Director

Humacyte, Inc.

Security class: Common Stock
Shares / value: 0
Estimated value: $0
Report date: 20 Aug 2025
Price: $1.58
Ownership: By Ayabudge LLC

Form 4 holding President, CEO and Director, Director

Humacyte, Inc.

Security class: Stock Options (right to buy)
Shares / value: 311,100
Estimated value
Report date: 16 Nov 2025
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding President, CEO and Director, Director

Humacyte, Inc.

Security class: Stock Options (right to buy)
Shares / value: 80,000
Estimated value
Report date: 11 Jun 2026
Price
Ownership: By spouse
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Laura E. Niklason

4 HUMA

Humacyte, Inc.

Report period: 11 Jun 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 12 Jun 2026, 17:57
Role: President, CEO and Director, Director
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 16 Nov 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 17 Nov 2025, 17:48
Role: President, CEO and Director, Director
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 18 Aug 2025
Transactions: 3
Transaction value: -$3,733,191
Accepted by SEC: 20 Aug 2025, 19:29
Role: President, CEO and Director, Director
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 12 Jun 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 16 Jun 2025, 16:31
Role: President, CEO and Director, Director
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 21 Jan 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 23 Jan 2025, 16:34
Role: President, CEO and Director, Director
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 19 Dec 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 20 Dec 2024, 17:09
Role: President, CEO and Director, Director
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 19 Nov 2024
Transactions: 1
Transaction value: +$7,979
Accepted by SEC: 21 Nov 2024, 07:31
Role: President, CEO and Director, Director
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 18 Nov 2024
Transactions: 3
Transaction value: -$6,606,799
Accepted by SEC: 20 Nov 2024, 19:06
Role: President, CEO and Director, Director
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 09 Sep 2024
Transactions: 2
Transaction value: -$2,364,521
Accepted by SEC: 11 Sep 2024, 17:50
Role: President, CEO and Director, Director
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 29 Aug 2024
Transactions: 1
Transaction value: +$7,998
Accepted by SEC: 03 Sep 2024, 16:23
Role: President, CEO and Director, Director
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 27 Aug 2024
Transactions: 3
Transaction value: -$5,724,139
Accepted by SEC: 29 Aug 2024, 18:48
Role: President, CEO and Director, Director
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 13 Jun 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 17 Jun 2024, 16:12
Role: President, CEO and Director, Director
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 11 Jun 2024
Transactions: 3
Transaction value: -$4,520,024
Accepted by SEC: 13 Jun 2024, 16:48
Role: President, CEO and Director, Director
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 04 Jun 2024
Transactions: 1
Transaction value: +$14,999
Accepted by SEC: 04 Jun 2024, 19:05
Role: President, CEO and Director, Director
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 03 Jun 2024
Transactions: 1
Transaction value: +$15,108
Accepted by SEC: 03 Jun 2024, 16:31
Role: President, CEO and Director, Director
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 31 May 2024
Transactions: 4
Transaction value: -$7,832,200
Accepted by SEC: 04 Jun 2024, 18:57
Role: President, CEO and Director, Director
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 08 Dec 2023
Transactions: 2
Transaction value: $0
Accepted by SEC: 12 Dec 2023, 16:09
Role: President, CEO and Director, Director
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 10 Oct 2023
Transactions: 2
Transaction value: +$136,160
Accepted by SEC: 10 Oct 2023, 16:08
Role: President, CEO and Director, Director
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 14 Sep 2023
Transactions: 1
Transaction value: -$5,560,000
Accepted by SEC: 15 Sep 2023, 16:06
Role: President, CEO and Director, Director
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 17 Aug 2023
Transactions: 3
Transaction value: -$6,378,837
Accepted by SEC: 21 Aug 2023, 18:07
Role: President, CEO and Director, Director
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 15 Jun 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 16 Jun 2023, 16:09
Role: President, CEO and Director, Director, 10%+ Owner
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 15 Jun 2023
Transactions: 1
Transaction value: -$1,558,750
Accepted by SEC: 16 Jun 2023, 16:04
Role: President, CEO and Director, Director, 10%+ Owner
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 13 Jun 2023
Transactions: 1
Transaction value: -$12,675,000
Accepted by SEC: 15 Jun 2023, 16:21
Role: President, CEO and Director, Director, 10%+ Owner
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 25 May 2023
Transactions: 1
Transaction value: -$7,218,750
Accepted by SEC: 26 May 2023, 17:05
Role: President, CEO and Director, Director, 10%+ Owner
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 01 Mar 2023
Transactions: 2
Transaction value: +$119,000
Accepted by SEC: 02 Mar 2023, 15:04
Role: President, CEO and Director, Director, 10%+ Owner
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 16 Dec 2022
Transactions: 1
Transaction value: -$606,031
Accepted by SEC: 19 Dec 2022, 19:23
Role: President, CEO and Director, Director, 10%+ Owner
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 15 Dec 2022
Transactions: 1
Transaction value: +$25,400
Accepted by SEC: 19 Dec 2022, 19:27
Role: President, CEO and Director, Director, 10%+ Owner
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 13 Dec 2022
Transactions: 3
Transaction value: -$1,945,509
Accepted by SEC: 15 Dec 2022, 18:51
Role: President, CEO and Director, Director, 10%+ Owner
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 08 Dec 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 12 Dec 2022, 15:11
Role: President, CEO and Director, Director, 10%+ Owner
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 15 Sep 2022
Transactions: 1
Transaction value: +$8,280
Accepted by SEC: 19 Sep 2022, 16:48
Role: President, CEO and Director, Director, 10%+ Owner
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 15 Sep 2022
Transactions: 1
Transaction value: -$6,090,000
Accepted by SEC: 19 Sep 2022, 16:36
Role: President, CEO and Director, Director, 10%+ Owner
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 09 Jun 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 13 Jun 2022, 16:21
Role: President, CEO and Director, Director, 10%+ Owner
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 23 May 2022
Transactions: 1
Transaction value: +$48,300
Accepted by SEC: 25 May 2022, 10:21
Role: President, CEO and Director, Director, 10%+ Owner
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 14 Dec 2021
Transactions: 4
Transaction value: -$2,729,332
Accepted by SEC: 16 Dec 2021, 18:46
Role: President, CEO and Director, Director, 10%+ Owner
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 13 Oct 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 15 Oct 2021, 15:39
Role: President, CEO and Director, Director, 10%+ Owner
Next action: Open filing details

4 HUMA

Humacyte, Inc.

Report period: 26 Aug 2021
Transactions: 12
Transaction value: +$15,225,000
Accepted by SEC: 27 Aug 2021, 16:15
Role: President, CEO and Director, Director, 10%+ Owner
Next action: Open filing details

3 HUMA

Humacyte, Inc.

Report period: 26 Aug 2021
Transactions: 0
Transaction value: $0
Accepted by SEC: 27 Aug 2021, 16:14
Role: President, CEO and Director, Director, 10%+ Owner
Next action: Open filing details

Insider Reports History

Continue from this owner filing history

Reported holdings for Laura E. Niklason

Insider Reports Filed by Laura E. Niklason